Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy
- PMID: 14732721
- DOI: 10.1161/01.HYP.0000116223.97436.e5
Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy
Abstract
Hypertension resistant to 2 antihypertensive drugs is more common among obese patients than among lean patients. The case we describe and the observations we report suggest that refractoriness among obese hypertensives is frequently caused by obstructive sleep apnea and/or inappropriately high plasma aldosterone levels. In other words, obese hypertensives may have sleep apnea, obese hypertensives without sleep apnea may have inappropriately elevated levels of plasma aldosterone, and a surprising number of obese patients with sleep apnea also have elevated levels of aldosterone. The mechanisms by which obesity and obstructive sleep apnea increase aldosterone levels and raise blood pressure are not understood, but sympathetic nervous system activation and production of nonclassical adrenal stimuli are two possibilities. Obstructive sleep apnea can be detected with a careful history and various sleep studies. Inappropriately elevated aldosterone levels can be detected by measuring the ratio of plasma aldosterone concentration to plasma renin activity. Successful treatment of these resistant hypertensives often can be achieved by devices that provide positive pressure to the upper airway to correct obstructive sleep apnea and by incorporating an aldosterone antagonist in the therapeutic regimen.
Similar articles
-
Sleep apnea, aldosterone, and resistant hypertension.Prog Cardiovasc Dis. 2009 Mar-Apr;51(5):371-80. doi: 10.1016/j.pcad.2008.02.004. Prog Cardiovasc Dis. 2009. PMID: 19249443 Review.
-
Treatment resistant hypertension.Am J Ther. 2008 Jul-Aug;15(4):351-5. doi: 10.1097/MJT.0b013e318164c67b. Am J Ther. 2008. PMID: 18645339
-
A randomized controlled study of CPAP effect on plasma aldosterone concentration in patients with resistant hypertension and obstructive sleep apnea.J Hypertens. 2014 Aug;32(8):1650-7; discussion 1657. doi: 10.1097/HJH.0000000000000238. J Hypertens. 2014. PMID: 24879492 Clinical Trial.
-
[Sleep apnea syndrome -- cause of resistance to treatment of arterial hypertension].Pneumologia. 2011 Oct-Dec;60(4):202-7. Pneumologia. 2011. PMID: 22420169 Review. Romanian.
-
[Obstructive sleep apnea--a risk factor for arterial hypertension].Wien Klin Wochenschr. 1989 Mar 17;101(6):200-3. Wien Klin Wochenschr. 1989. PMID: 2711693 German.
Cited by
-
Nocturia and obstructive sleep apnoea.Nat Rev Urol. 2024 May 23. doi: 10.1038/s41585-024-00887-7. Online ahead of print. Nat Rev Urol. 2024. PMID: 38783115 Review.
-
Cardiovascular Disease in Obstructive Sleep Apnea: Putative Contributions of Mineralocorticoid Receptors.Int J Mol Sci. 2023 Jan 23;24(3):2245. doi: 10.3390/ijms24032245. Int J Mol Sci. 2023. PMID: 36768567 Free PMC article. Review.
-
Primary aldosteronism and obstructive sleep apnea: What do we know thus far?Front Endocrinol (Lausanne). 2022 Sep 29;13:976979. doi: 10.3389/fendo.2022.976979. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36246876 Free PMC article. Review.
-
Who should be screened for primary aldosteronism? A comprehensive review of current evidence.J Clin Hypertens (Greenwich). 2022 Sep;24(9):1194-1203. doi: 10.1111/jch.14558. J Clin Hypertens (Greenwich). 2022. PMID: 36196469 Free PMC article. Review.
-
Primary Aldosteronism and Resistant Hypertension: A Pathophysiological Insight.Int J Mol Sci. 2022 Apr 27;23(9):4803. doi: 10.3390/ijms23094803. Int J Mol Sci. 2022. PMID: 35563192 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical